

بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات لم ترد بالأصل



ADVANCED GLYCATION END PRODUCTS AND CARDIO-RENAL FUNCTIONS IN DIABETIC ELDERLY

Thesis

Submitted for Partial Fulfillment of MD Degree
In Geriatric and Gerontology

By

Heba Shreif Mahmmoud Elsobky

Assistant Lecturer of Geriatrics, Specialized Internal Medicine Hospital
Faculty of Medicine - Mansoura University

Supervised by

Prof. Dr. Moatassem Salah Amer

Professor of Geriatrics & Gerontology and Internal Medicine
Faculty of Medicine - Ain Shams University

Prof. Dr. Sarah Ahmed Hamza

Professor of Geriatrics and Gerontology
Faculty of Medicine - Ain Shams University

Prof. Dr. Samia Ahmed Abdul-Rahman

Assistant Professor of Geriatrics & Gerontology
Faculty of Medicine - Ain Shams University

Dr. Heba Gamal Eldin Ahmed Saber

Lecturer of Geriatrics & Gerontology
Faculty of Medicine - Ain Shams University

Dr. Marwa Abdel Azeem Abdel Gawad Ali

Lecturer of Geriatrics & Gerontology
Faculty of Medicine - Ain Shams University

Dr. Mohammed Salah Ahmed Hussein

Lecturer of Cardiovascular Medicine
Faculty of Medicine - Mansoura University

Faculty of Medicine
Ain Shams University

2020

List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	IV
▪ List of Figures	VI
▪ Introduction	1
▪ Aim of the Work	3
▪ Review of Literature	
- Advanced glycation end products	4
- Advanced glycation end products and diabetic complications in elderly	22
▪ Subjects and Methods	58
▪ Results	66
▪ Discussion	79
▪ Summary	89
▪ Conclusion	90
▪ Recommendations	91
▪ References	92
▪ Appendix	147
▪ Arabic Summary	--

List of Abbreviations

AHF	Acute heart failure
AMI	Acute myocardial infarction
AGER1	Advanced glycation end products receptor 1
AGEs	Advanced glycation end products
AD	Alzheimer's disease
ACE	Angiotensin converting enzyme
ACEIS	Angiotensin converting enzyme inhibitors
AT1R	Angiotensin II type 1 receptor
ARBs	Angiotensin Receptor Blockers
ADMA	Asymmetric dimethyl arginine
ABS	Australian Bureau of Statistics
BBs	Beta-blockers
BMI	Body mass index
CCBs	Calcium channel blockers
CML	Carboximethyl-lysine
CRS	Cardio -renal syndrome
CVD	Cardiovascular diseases
CKD	Chronic kidney disease
COPD	Chronic obstructive pulmonary disease
CAD	Coronary artery disease
CRP	C-reactive protein
DM	Diabetes mellitus
DCM	Diabetic cardiomyopathy
DKD	Diabetic kidney disease
DN	Diabetic nephropathy

List of Abbreviations

DBP	Diastolic blood pressure
EF	Ejection fraction
ECHO	Echocardiography
ECG	Electrocardiogram
ESRD	End-stage renal disease
ECM	Extracellular matrix
FBS	Fasting blood sugar
GBM	Glomerular basement membranes
GFR	Glomerular filtration rate
HBA1C	Glycosylated hemoglobin
Hb	Hemoglobin
HF	Heart Failure
HDL	High-density lipoproteins
IDF	International Diabetes Federation
IR	Insulin resistance
IL6	Interleukin 6
LVEF	Left ventricular ejection fraction
LVH	Left ventricular hypertrophy
LDL	Low density lipoprotein
MG	Methylglyoxal
MA	Microalbuminuria
MCP-1	Monocyte chemo-attract protein-1
MI	Myocardial infarction
NYHA	New York Heart Association
NADPH	Nicotinamide adenine dinucleotide phosphate

List of Abbreviations

NO	Nitric oxide
OS	Oxidative stress
PD	Parkinson's disease
ROS	Reactive oxygen species
RAGE	Receptor for AGEs
RAAS	Renin angiotensin-aldosterone system
SAF	Skin auto-fluorescence
SBP	Systolic blood pressure
US	Ultrasonography
TGF-β	Transforming growth factor-beta
TG	Triglyceride
TNF-α	Tumor necrosis factor α
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
VEGF	Vascular endothelial growth factor

List of Tables

Table No.	Title	Page
Table (1):	Description of the sociodemographic data among the studied groups	66
Table (2):	Description of the clinical examination parameters among the studied groups	67
Table (3):	Description of cardio-renal complications among the cases	67
Table (4):	Description of the drugs used by the cases.....	68
Table (5):	Level of the AGEs among the studied groups	68
Table (6):	Levels of the laboratory measures among the studied groups	69
Table (7):	Comparison of demographic characteristics among the studied groups	70
Table (8):	Comparison of the clinical examination parameters among the studied groups	71
Table (9):	Comparison of the clinical examination parameters among the cases and control groups.....	72
Table (10):	Comparison between the cases regarding pharmacological treatment ..	73

List of Tables (Continued)

Table No.	Title	Page
Table (11):	Levels of the lab measures among the studied groups	74
Table (12):	AGEs among the studied groups	75
Table (13):	AGEs among the cases	75
Table (14):	Comparison of the lab investigations among the cases and control groups....	77
Table (15):	Correlation between AGEs and other variables among studied groups	78

List of Figures

Figure No.	Title	Page
Fig. (1):	AGEs among the studied groups	76

Abstract

Background: Diabetes mellitus is a group of diseases characterized by metabolic disturbances with increasing prevalence worldwide. Individuals with diabetes mellitus present with several micro- and macro vascular complications such as retinopathy, nephropathy, neuropathy, atherosclerosis and cardiovascular disease. A higher body mass index (BMI) raises the risk of having uncontrolled diabetes and complications related to it, such as heart disease, stroke, kidney failure, nervous system and eye problems. However, recent studies have reported that being overweight may confer a protective effect against all-cause mortality and on the life expectancy of diabetic patients; this has been termed the obesity paradox. The aim to explore the association between BMI and diabetic complications among elderly patients with type 2 diabetes.

Methods: A case-control study was conducted on 60 elderly diabetic males and females aged ≥ 60 years recruited from the inpatient wards and outpatient clinics of Mansoura university hospitals. The sample was divided into 3 groups: the first group was comprised of 26 elderly diabetic patients with normal BMI. The second group was comprised of 24 overweight elderly diabetic. The third group was comprised of 10 obese elderly diabetic. Full history taking, clinical examination, BMI measurement (kg/m²) were obtained from all participants.

Results: The current study showed that there was insignificant differences regarding BMI between the study groups. Hyperglycemic and hypoglycemic coma were least frequent among obese cases, while neuropathy was more frequent among cases with normal BMI. But neither of these relationships was statistically significant

Conclusions: Any increase in BMI above normal weight levels was not associated with an increased risk of having complications of diabetes mellitus.

Keywords: Diabetes mellitus; diabetes mellitus complications; body mass index; elderly; Egyptian

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder of great impact worldwide (*Shaw et al., 2010*). The International Diabetes Federation (IDF) estimates around 415 million people had DM in 2015 and this number is expected to rise to 642 million by 2040 (*IDF, 2016*).

The prevalence of type 2 diabetes mellitus (T2DM) in Egypt is around 15.6% of all adults aged 20 to 79 years (*Hegazi et al., 2015*).

The importance of hyperglycemia in the pathogenesis of diabetic complications has been established. Hyperglycemia causes cell injury by formation of advanced glycation end products (AGEs) (*Duckworth et al., 2009*). Diabetic patients were shown to have higher AGEs levels when compared with normal individuals (*Huebschmann et al., 2006*).

AGEs are proteins or lipids that become glycated as a result of exposure to sugars (*Vistoli et al., 2013*). Under physiologic conditions, formation of AGEs occurs slowly (*Goldin et al., 2006*). Hyperglycemia, hyperlipidemia and oxidative stress(OS) accelerate formation of AGEs by non-enzymatic glycation reactions (*Beisswenger et al., 2012*).

AGEs accumulate in the human, and the effects of their high concentration are found in every tissue and organs (*Semba et al., 2009*).